Cyberonics VNS Depression Treatment Panel Review Tentatively Set For June
This article was originally published in The Gray Sheet
Executive Summary
FDA's Neurological Devices Advisory Panel will review a PMA supplement for Cyberonics' VNS Therapy depression indication June 15, the firm says
You may also be interested in...
Cyberonics panel date finalized
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...
Cyberonics panel date finalized
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...
Cyberonics Moves Up VNS Depression Timetable Four Months; Costs Rise
Cyberonics is preparing for an April FDA panel review of its VNS Therapy vagus nerve stimulation device for depression